$123.96
+0.02 (+0.02%)
NUVL News5 articles
AbbVie Acquires Apogee Therapeutics for $10.9B in Cash, Bolstering Pipeline
AbbVie announced a $10.9 billion cash acquisition of Apogee Therapeutics, adding a promising eczema treatment to its pipeline as it seeks to offset declining Humira sales.
GSK's $10.6B Nuvalent Buyout Drives Shares Near $124 Offer Price
Nuvalent stock rose 39.28% to $123.25 after GSK agreed to acquire the biotech for $124/share in cash, narrowing the spread to 0.6% as investors pivot to merger-arb dynamics and FDA dates.
Wall Street Mixed as AI Rally Faces Key Inflation Test
U.S. stocks traded mixed Tuesday as the Dow and S&P 500 posted modest gains while the Nasdaq dipped, with market focus on upcoming inflation data and AI sector strength.
GSK's $10.6B Nuvalent Bid Drives Stock Near Offer Price
Nuvalent shares jumped 38.9% to $122.93 after GSK's $10.6 billion buyout offer, as investors bet on the deal closing with two lead lung-cancer drugs under FDA review.
GSK Acquires Nuvalent for $10.6B in Oncology Push Ahead of HIV Patent Cliff
GSK buys Nuvalent for $10.6B, paying a 40% premium, to strengthen its oncology portfolio and offset upcoming HIV drug patent losses.